Network-based drug repurposing identifies small molecule drugs as immune checkpoint inhibitors for endometrial cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Network-based drug repurposing identifies small molecule drugs as immune checkpoint inhibitors for endometrial cancer

Published:2024-01-16 Issue: Volume: Page:
ISSN:1381-1991
Container-title:Molecular Diversity
language:en
Short-container-title:Mol Divers

Author:

Ahmed Faheem,Samantasinghar Anupama,Ali Wajid,Choi Kyung Hyun

Funder

This work was supported by 2023 Jeju National University, South Korea

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s11030-023-10784-7.pdf

Reference93 articles.

1. Rodrigues R, Duarte D, Vale N (2022) Drug repurposing in cancer therapy: influence of patient’s genetic background in breast cancer treatment. Int J Mol Sci. https://doi.org/10.3390/IJMS23084280

2. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. CA Cancer J Clin 65(2):87–108. https://doi.org/10.3322/CAAC.21262

3. Zou Y, Xu Y, Chen X, Zheng L (2023) Advances in the application of immune checkpoint inhibitors in gynecological tumors. Int Immunopharmacol 117:109774. https://doi.org/10.1016/j.intimp.2023.109774

4. Lin CK, Liu ST, Wu ZS, Wang YC, Huang SM (2021) Mechanisms of cisplatin in combination with repurposed drugs against human endometrial carcinoma cells. Life (Basel, Switzerland) 11(2):1–18. https://doi.org/10.3390/LIFE11020160

5. Gómez-Raposo C, Merino Salvador M, Aguayo Zamora C, García de Santiago B, Casado Sáenz E (2021) Immune checkpoint inhibitors in endometrial cancer. Crit Rev Oncol Hematol 161:103306. https://doi.org/10.1016/J.CRITREVONC.2021.103306

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Repurposing lipid-lowering drugs on asthma and lung function: evidence from a genetic association analysis;Journal of Translational Medicine;2024-07-03

2. Integrated edge information and pathway topology for drug-disease associations;iScience;2024-07

3. Accurate prediction of drug combination risk levels based on relational graph convolutional network and multi-head attention;Journal of Translational Medicine;2024-06-16

4. Tribulations and future opportunities for artificial intelligence in precision medicine;Journal of Translational Medicine;2024-04-30

5. Architecting the metabolic reprogramming survival risk framework in LUAD through single-cell landscape analysis: three-stage ensemble learning with genetic algorithm optimization;Journal of Translational Medicine;2024-04-15

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3